MD2 激活蛋白激酶（AMP）增强了非酒精性脂肪性肝病（NAFLD）中脂质积累与炎症之间的联系。 - Suppr

MD2 AMP(K)s up the link between lipid accumulation and inflammation in NAFLD.

作者信息

Heldens Anneleen, Lefere Sander

机构信息

Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Liver Research Center Ghent, Ghent University, Ghent, Belgium.

Gut-Liver Immunopharmacology Unit, Department of Basic and Applied Medical Sciences, Liver Research Center Ghent, Ghent University, Ghent, Belgium.

出版信息

Clin Transl Med. 2022 Apr;12(4):e832. doi: 10.1002/ctm2.832.

DOI:10.1002/ctm2.832

PMID:35452173

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9028087/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be52/9028087/5e6a934e6aad/CTM2-12-e832-g001.jpg

相似文献

MD2 AMP(K)s up the link between lipid accumulation and inflammation in NAFLD.MD2 激活蛋白激酶（AMP）增强了非酒精性脂肪性肝病（NAFLD）中脂质积累与炎症之间的联系。

Clin Transl Med. 2022 Apr;12(4):e832. doi: 10.1002/ctm2.832.

Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.抑制 MD2 依赖性炎症可减轻非酒精性脂肪性肝病的进展。

J Cell Mol Med. 2018 Feb;22(2):936-947. doi: 10.1111/jcmm.13395. Epub 2017 Oct 27.

N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1.CREBH 的 N-糖基化通过调节 PPARα 和 SCD-1 改善了 NAFLD 中的脂质代谢并减轻了脂毒性。

FASEB J. 2020 Nov;34(11):15338-15363. doi: 10.1096/fj.202000836RR. Epub 2020 Sep 30.

Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.巨噬细胞清道夫受体1介导非酒精性脂肪性肝病中的脂质诱导炎症。

J Hepatol. 2022 May;76(5):1001-1012. doi: 10.1016/j.jhep.2021.12.012. Epub 2021 Dec 21.

Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.在非酒精性脂肪性肝病样情况下，细胞内脂质是肝损伤和慢性肾脏病的一个独立原因。

Mol Metab. 2018 Oct;16:100-115. doi: 10.1016/j.molmet.2018.07.006. Epub 2018 Aug 1.

Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.蒙古黄芪多糖可改善非酒精性脂肪性肝病大鼠的肝脂质蓄积和炎症，并调节肠道微生物群。

Food Funct. 2022 Jul 4;13(13):7287-7301. doi: 10.1039/d2fo01009g.

Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING.瑞德西韦通过抑制STING来调节肝细胞血脂异常和炎症，从而减轻高脂饮食（HFD）诱导的非酒精性脂肪性肝病（NAFLD）。

Biochem Biophys Res Commun. 2020 May 28;526(2):381-388. doi: 10.1016/j.bbrc.2020.03.034. Epub 2020 Mar 27.

Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice.壳寡糖通过减少 C57BL/6 小鼠的脂肪积累、炎症和氧化应激来减轻高脂饮食诱导的非酒精性脂肪肝病。

Mar Drugs. 2019 Nov 16;17(11):645. doi: 10.3390/md17110645.

Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.四妙方通过调节肝脏脂质代谢和肠道微生物群来减轻非酒精性脂肪性肝病。

Phytomedicine. 2021 May;85:153544. doi: 10.1016/j.phymed.2021.153544. Epub 2021 Mar 10.

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products.肝脏AMP激酶作为治疗非酒精性脂肪性肝病的潜在靶点：来自天然产物研究的证据

Curr Med Chem. 2018;25(8):889-907. doi: 10.2174/0929867324666170404142450.

本文引用的文献

Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.全基因组功能获得性筛选鉴定出 EZH2 介导的食管鳞癌对 PI3Kα 抑制剂的耐药性。

Clin Transl Med. 2022 May;12(5):e835. doi: 10.1002/ctm2.835.

MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.MD2 缺乏通过调节非酒精性脂肪肝病中的 TBK1 来防止高脂肪饮食诱导的 AMPK 抑制和脂质积累。

Clin Transl Med. 2022 Mar;12(3):e777. doi: 10.1002/ctm2.777.

Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2.运动诱导的鸢尾素通过与 MD2 的竞争性结合减少炎症并改善非酒精性脂肪性肝病。

Cells. 2021 Nov 25;10(12):3306. doi: 10.3390/cells10123306.

Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism.肥胖与非酒精性脂肪性肝病中的巨噬细胞：与代谢的相互作用

JHEP Rep. 2019 Feb 23;1(1):30-43. doi: 10.1016/j.jhepr.2019.02.004. eCollection 2019 May.

Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.非酒精性脂肪性肝炎治疗的当前及新出现的方法

Gene Expr. 2019 Nov 4;19(3):175-185. doi: 10.3727/105221619X15536120524171. Epub 2019 Apr 2.

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD.遗传肝脏特异性 AMPK 激活可预防饮食诱导的肥胖和非酒精性脂肪性肝病。

Cell Rep. 2019 Jan 2;26(1):192-208.e6. doi: 10.1016/j.celrep.2018.12.036.

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.全球视角下的非酒精性脂肪性肝病和非酒精性脂肪性肝炎。

Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251.

Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids.肥胖、炎症、Toll 样受体 4 和脂肪酸。

Nutrients. 2018 Mar 30;10(4):432. doi: 10.3390/nu10040432.

TRIF as a Novel Modulator of Liver Inflammation and Fibrosis.TRIF作为肝脏炎症和纤维化的新型调节因子。

Cell Mol Gastroenterol Hepatol. 2017 Mar 22;3(3):299-300. doi: 10.1016/j.jcmgh.2017.03.002. eCollection 2017 May.

Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice.髓样分化因子-2 和 Toll 样受体 4 表达缺失可减轻小鼠非酒精性脂肪性肝炎和肝纤维化。

Am J Physiol Gastrointest Liver Physiol. 2011 Mar;300(3):G433-41. doi: 10.1152/ajpgi.00163.2009. Epub 2011 Jan 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

MD2 AMP(K)s up the link between lipid accumulation and inflammation in NAFLD.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献